Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
Más filtros

Base de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Curr Res Transl Med ; 67(1): 20-27, 2019 02.
Artículo en Inglés | MEDLINE | ID: mdl-30104160

RESUMEN

PURPOSE OF THE STUDY: Mesenchymal stromal cells (MSCs) are considered a promising tool for cell therapy approaches. The translation of research-based cell culture protocols into procedures that comply with Good Manufacturing Practice (GMP) is critical. The aim of this study was to design a new method for the expansion of MSCs from Adipose Tissue (AT-MSCs) in compliance with GMP, without enzymatic tissue digestion and without the use of animal proteins as source of growth factors. PATIENTS AND METHODS: MSCs were expanded from 10 periumbilical biopsies. Our new isolation approach is based on: (1) disruption of AT with an automated, closed system; (2) use of GMP-grade medium without the addition of fetal bovine serum or platelet lysate; (3) use of human recombinant Trypsin. AT-MSCs cultured in α-MEM and minced by scalpel were used as control. RESULTS: It was possible to expand MSCs from all the AT-samples for at least eight passages. MSCs displayed the typical spindle-shape morphology, a high viability, multilineage differentiation potential and high expression levels of the typical MSC-specific surface antigens and genes. Compared to standard method, MSCs obtained with the new method showed higher yield, up to passage 6, and higher purity in terms of percentage of CD34 and CD45 markers. All AT-MSCs exhibit in vitro immunosuppressive capacity and possess a normal karyotype. CONCLUSIONS: Our data clearly demonstrate that our new approach permits to generate AT-MSCs fully compliant for therapeutic use and better at least in terms of quantity and purity than those obtained with the standard method.


Asunto(s)
Tejido Adiposo/citología , Separación Celular/métodos , Tratamiento Basado en Trasplante de Células y Tejidos/métodos , Células Madre Mesenquimatosas/citología , Adulto , Anciano , Diferenciación Celular , Proliferación Celular , Células Cultivadas , Femenino , Humanos , Masculino , Persona de Mediana Edad
2.
Artículo en Inglés | MEDLINE | ID: mdl-28101929

RESUMEN

The aim of the study was to evaluate taste disorders in patients receiving chemotherapy and to assess the impact of dysgeusia on patients' health-related quality of life (HRQOL). A total of 289 patients with a diagnosis of malignant solid or haematological cancer undergoing chemotherapy completed a questionnaire assessing dysgeusia and HRQOL. Sixty-four per cent of patients developed dysgeusia after and during chemotherapy. A statistically significant correlation was found between type of cancer and dysgeusia (p = .012), moreover a statistically significant association was found between type of chemotherapy and occurrence of dysgeusia (p = .031). Patients with dysgeusia had a worse overall HRQOL than those who did not have dysgeusia, and the association between HRQOL and dysgeusia was also statistically significant (p = .003). Patients with dysgeusia had a higher probability of having a worse HRQOL (p = .002). In line with previous studies, we observed a significant correlation between chemotherapy and dysgeusia. Furthermore, this study found that cancer patients with dysgeusia have a lower quality of life. In particular the domains "role," "social aspect," "nausea-vomiting" and "appetite" are most influenced by dysgeusia. Improving the communication and information to patients considered at higher risk of developing dysgeusia can have a positive impact on patients' quality of life.


Asunto(s)
Antineoplásicos/efectos adversos , Disgeusia/inducido químicamente , Neoplasias/tratamiento farmacológico , Calidad de Vida , Anciano , Anorexia/inducido químicamente , Antraciclinas/efectos adversos , Antibióticos Antineoplásicos/efectos adversos , Antineoplásicos Alquilantes/efectos adversos , Bortezomib/efectos adversos , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias Colorrectales/diagnóstico por imagen , Estudios Transversales , Femenino , Estado de Salud , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Linfoma/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Náusea/inducido químicamente , Compuestos de Platino/efectos adversos , Reproducibilidad de los Resultados , Rol , Encuestas y Cuestionarios , Taxoides/efectos adversos , Alcaloides de la Vinca/efectos adversos , Vómitos/inducido químicamente
4.
Genes Chromosomes Cancer ; 46(11): 961-71, 2007 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17647282

RESUMEN

The clinical course of myxoid/round cell liposarcoma (MRCL) is characterized by frequent local recurrences and metastases at unusual sites. MRCLs carry specific translocations, t(12;16) or rarely t(12;22), linking the FUS or the EWSR1 gene with the DDIT3 gene, respectively. Nine FUS/DDIT3 and three EWSR1/DDIT3 variants of fusion transcripts have been described thus far. In search of prognostic markers for MRCL, we analyzed the translocation types of 31 patients and related them to the event free and overall survival. Using break-apart FISH and RT-PCR combined with DNA sequencing, we detected FUS/DDIT3 fusions in 30 sarcomas, while an EWSR1/DDIT3 translocation was identified in one tumor. FUS/DDIT3 type II (exons 5-2) was most commonly detected (20 cases), followed by type I (7-2) (7 cases) and type III (8-2) (3 cases). A single tumor carrying a t(12;22) translocation expressed a hitherto unknown EWSR1-DDIT3 fusion transcript (13-3) linking the complete RNA-binding domain of EWSR1 with a short piece of the 5'-UTR and the entire open reading frame of the DDIT3 gene. Interestingly, five of six patients with type I (7-2) FUS/DDIT3 fusions displayed local recurrences and/or metastatic spread within the first 3 years, generally requiring chemotherapeutical treatment (median disease-free survival 17 months). In contrast, 9 of 13 patients with type II FUS/DDIT3 translocations remained at 3 years disease-free (median disease-free survival 75 months). Since the total number of patients is still limited, further studies are required to verify a putative association of type I FUS/DDIT3-fusion transcripts with a prognosis of MRCL.


Asunto(s)
Proteínas de Unión a Calmodulina/genética , Liposarcoma Mixoide/genética , Proteínas de Fusión Oncogénica/genética , Proteínas de Unión al ARN/genética , Proteínas Recombinantes de Fusión/genética , Proteínas Represoras/genética , Factor de Transcripción CHOP/genética , Translocación Genética , Adolescente , Adulto , Anciano , Secuencia de Bases , Cromosomas Humanos Par 12 , Cromosomas Humanos Par 16 , Cromosomas Humanos Par 22 , Cartilla de ADN , Femenino , Humanos , Hibridación Fluorescente in Situ , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Proteína EWS de Unión a ARN
5.
Oncogene ; 26(23): 3440-9, 2007 May 17.
Artículo en Inglés | MEDLINE | ID: mdl-17130827

RESUMEN

Inactivation of the HRPT2 gene encoding parafibromin was recently linked to the familial hyperparathyroidism-jaw tumor syndrome. Patients with this syndrome carry an increased risk of parathyroid and renal tumors. To determine the relevance of HRPT2 for sporadic renal tumors, clear cell, papillary and chromophobe renal cell carcinomas as well as oncocytomas and Wilms tumors were analysed for HRPT2 gene alterations. Loss of heterozygosity (LOH) of HRPT2 was found in seven of 56 (12.5%) clear cell, three of 14 (21%) papillary, six of 10 (60%) chromophobe renal cell carcinomas, three of eight (38%) oncocytomas and four of 10 (40%) Wilms tumors. In addition, two novel HRPT2 point mutations, causing K34Q and R292K changes in parafibromin, were detected in one clear cell carcinoma and one Wilms tumor, respectively. These tumors displayed LOH of the remaining wild-type allele, but interestingly no von Hippel-Lindau (VHL) mutation. Functional analysis revealed that the K34Q mutant species of parafibromin is, unlike wild-type protein, defective in suppressing cyclin D1 expression in vivo. Taken together, these results suggest that renal cancer-associated mutations in parafibromin occur in the absence of VHL mutation, which in turn may contribute to constitutively elevated cyclin D1 expression and abnormal cell proliferation.


Asunto(s)
Desequilibrio Alélico/genética , Neoplasias Renales/genética , Mutación/genética , Proteínas Supresoras de Tumor/genética , Anciano , Anciano de 80 o más Años , Alelos , Secuencia de Bases , Cromosomas Humanos Par 1/genética , Femenino , Heterocigoto , Humanos , Lisina/genética , Masculino , Persona de Mediana Edad
6.
Neurol Sci ; 27(4): 261-5, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16998730

RESUMEN

The objective was to evaluate pravastatin modulation on peripheral blood mononuclear cell (PBMC) migration across endothelial monolayers. Eleven hypercholesterolaemic patients were treated with pravastatin 20 mg/day. At baseline (T0), after 40 days (T40) and after 6 months (T 6 months) of treatment total serum cholesterol, low-density lipoprotein (LDL), high-density lipoprotein, triglycerides, C-reactive protein, as well as tumour necrosis factor-alpha (TNF-alpha) and metalloproteinases-9 plasma levels were evaluated. At the same time points the effect of pravastatin on migration of PBMCs through a monolayer of murine brain endothelial cells was studied both in basal conditions and after endothelial stimulation with recombinant mouse TNF-alpha 10 ng/ml for 24 h. Seven volunteers were used as healthy controls. Significant decreases in total cholesterol, LDL and triglycerides as well as inhibition of transmigration were observed. PBMCs transmigration in patients prior to pravastatin therapy was higher than in healthy controls. These results suggest that pravastatin could be of benefit in a spectrum of diseases characterised by extravasation of PBMCs into the central nervous system.


Asunto(s)
Anticolesterolemiantes/farmacología , Movimiento Celular/efectos de los fármacos , Hipercolesterolemia/patología , Leucocitos Mononucleares/efectos de los fármacos , Pravastatina/farmacología , Anciano , Endotelio/efectos de los fármacos , Endotelio/fisiopatología , Ensayo de Inmunoadsorción Enzimática/métodos , Femenino , Humanos , Hipercolesterolemia/tratamiento farmacológico , Leucocitos Mononucleares/fisiología , Masculino , Metaloproteinasa 9 de la Matriz/metabolismo , Persona de Mediana Edad , Factores de Tiempo , Factor de Necrosis Tumoral alfa/metabolismo
7.
Ther Umsch ; 63(4): 279-85, 2006 Apr.
Artículo en Alemán | MEDLINE | ID: mdl-16689460

RESUMEN

According to the current WHO classification of haematopoietic and lymphoid tissue, recurrent genetic aberrations constitute diagnostic markers for the histomorphological diagnosis of malignancies in these tissues. In lymphoma, translocations represent such genetic aberrations. Apart from their diagnostic impact, there is increasing evidence for their prognostic and predictive value. Despite the numerous translocations known in Non-Hodgkin's lymphoma (NHL), few are applied in routine diagnostics on a regular basis. To date, translocations have gained particular significance in B-cell NHLs, in contrast to T-cell NHLs where few are characterised. Refined tissue processing facilitates determination of translocations not only in fresh tissue, but increasingly also informalin fixed, paraffin embedded, and even decalcified biopsies. Hybridisation procedures (Southern blotting, FISH) and gene amplification methods (PCR, RT-PCR) are the primary molecular techniques employed to identify translocations. The article deals with the advantages and disadvantages of the currently used molecular techniques for the investigation of translocations in routine hematopathology diagnostics.


Asunto(s)
Linfoma no Hodgkin/genética , Translocación Genética , Apoptosis , Biopsia , Southern Blotting , Citogenética , Diagnóstico Diferencial , Humanos , Hibridación Fluorescente in Situ , Linfoma de Células B/diagnóstico , Linfoma de Células B/genética , Linfoma de Células B/patología , Linfoma no Hodgkin/diagnóstico , Linfoma no Hodgkin/patología , Linfoma de Células T/diagnóstico , Linfoma de Células T/genética , Linfoma de Células T/patología , Técnicas de Diagnóstico Molecular , Adhesión en Parafina , Reacción en Cadena de la Polimerasa , Valor Predictivo de las Pruebas , Pronóstico , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Organización Mundial de la Salud
8.
Neuroscience ; 137(4): 1211-9, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16359809

RESUMEN

Brain inflammation is a common event in the pathogenesis of several neurological diseases. It is unknown whether leukocyte/endothelium interactions are sufficient to promote homing of blood-borne cells into the brain compartment. The role of mononuclear cells and endothelium was analyzed in a new experimental model, the isolated guinea-pig brain maintained in vitro by arterial perfusion. This preparation allows one to investigate early steps of brain inflammation that are impracticable in vivo. We demonstrate by confocal microscopy analysis that in vitro co-perfusion of pro-inflammatory agents and pre-activated fluorescent mononuclear cells induced endothelial expression of selectins and intracellular adhesion molecule-1 in correspondence of arrested mononuclear cells, and correlates with a moderate increase in blood-brain barrier permeability. Separate perfusion of pro-inflammatory agents and mononuclear cells induced neither mononuclear cell adhesion nor adhesion molecule expression. We demonstrate that co-activation of mononuclear cells and cerebral endothelium is an essential requirement for cell arrest and adhesion in the early stages of experimental cerebral inflammation.


Asunto(s)
Circulación Cerebrovascular/fisiología , Endotelio Vascular/fisiopatología , Inflamación/fisiopatología , Animales , Supervivencia Celular , Modelos Animales de Enfermedad , Endotelio Vascular/patología , Cobayas , Técnicas In Vitro , Inflamación/patología , Microscopía Confocal
9.
Exp Cell Res ; 308(2): 273-82, 2005 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-15936757

RESUMEN

In this work, we isolated and produced long-term cultures of human fetal endothelial cells (fECs) deriving from different organs of the same 12-week-old embryos. Highly pure endothelium cultures were obtained from specimens of brain, heart, lung, liver, aorta and kidney by using magnetic microspheres coated with CD31 or CD34 specific endothelial antibodies. The endothelial nature of these cells was confirmed by the presence of von Willebrand Factor (vWf), Flk-1/VEGFR2 and CD31. The fECs cultures showed organ-specific differences as regards to the morphological appearance, the growth rate and the expression of cellular adhesion molecules (CAMs) before or after stimulation by the inflammatory cytokines IL-1beta and TNF-alpha. For instance, TNF-alpha showed a specific effect on fetal heart ECs by stimulating E-selectin expression. Our findings indicate that fECs may represent an innovative tool to study differences among ECs of different vascular districts of the same individual, thus increasing the possibility to compare many pathological aspects of human adult and fetal microvasculature.


Asunto(s)
Moléculas de Adhesión Celular/metabolismo , Endotelio Vascular/metabolismo , Microcirculación/embriología , Neovascularización Fisiológica/fisiología , Vísceras/irrigación sanguínea , Vísceras/embriología , Antígenos de Superficie/inmunología , Biomarcadores/metabolismo , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/fisiología , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Citocinas/farmacología , Selectina E/metabolismo , Endotelio Vascular/citología , Feto , Humanos , Microcirculación/inmunología , Microcirculación/metabolismo , Especificidad de Órganos/fisiología , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/metabolismo , Receptor 2 de Factores de Crecimiento Endotelial Vascular/metabolismo , Factor de von Willebrand/metabolismo
10.
Ann Vasc Surg ; 19(1): 42-8, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15714366

RESUMEN

Visceral artery aneurysms (VAA) frequently present as life-threatening emergencies. The purpose of this study was to review our experience with VAA treatment. Between 1988 and April 2002, 31 VAA were treated in 28 patients (14 males, 14 females) with average age of 55 +/- 15 years. The most common locations were the splenic artery (16) and the hepatic artery (7). Three patients underwent emergency surgery, 22 patients had elective open surgery, and 7 patients underwent endovascular treatment. In the surgical group the perioperative mortality rate was 3.6%. The perioperative morbidity rate was 7.1% (one case of respiratory distress manifested in the immediate postoperative period and one urgent case of bilious fistula). In the endovascular group none of the patients died; the perioperative morbidity rate was of 14.3% (one case of hepatic artery thrombosis after failure of gastroduodenal artery aneurysm embolization). Failure of the procedure was 42.9% (3 cases of aneurysm recanalization). In conclusion, we believe that an aggressive surgical approach is justified, even in the case of asymptomatic VAA, because of the low morbidity and mortality rates. Endovascular treatment should be reserved for selected cases.


Asunto(s)
Abdomen/irrigación sanguínea , Aneurisma/cirugía , Adulto , Fístula Biliar/etiología , Implantación de Prótesis Vascular , Duodeno/irrigación sanguínea , Procedimientos Quirúrgicos Electivos , Embolización Terapéutica/efectos adversos , Urgencias Médicas , Femenino , Estudios de Seguimiento , Arteria Hepática/cirugía , Humanos , Masculino , Arteria Mesentérica Superior/cirugía , Persona de Mediana Edad , Complicaciones Posoperatorias , Estudios Retrospectivos , Arteria Esplénica/cirugía , Estómago/irrigación sanguínea , Tasa de Supervivencia , Trombosis/etiología , Insuficiencia del Tratamiento , Vísceras/irrigación sanguínea
11.
Ann Ital Chir ; 75(2): 157-65, 2004.
Artículo en Italiano | MEDLINE | ID: mdl-15386987

RESUMEN

Surgical treatment of pararenal aortic aneurysms, if compared to open repair of infrarenal aneurysms, is characterized by more technical difficulties and haemodynamic problems. Since endovascular repair has become feasible in most cases of infrarenal aneurysms, surgical treatment of pararenal aneurysms is a matter of great interest for vascular surgery. Detection of pararenal aneurysms needs a careful preoperative diagnosis, assessment of cardiac, renal and pulmonary status of the patient and planning of the surgical intervention. The surgeon needs to face an extended proximal aorta exposure, to manage the left renal vein and to choose an appropriate clamping site. Then a skilled and quick reconstruction of the visceral arteries is fundamental to minimize organ disfunction. Coupled intraoperative selective perfusion of visceral arteries and systemic administration of nephroprotective drugs optimizes organ protection during ischemia. To better define challenges, risks and results, we reviewed our experience with the treatment of pararenal aortic aneurysms. In the period between January 1993 and May 2003, 98 consecutive patients underwent surgery for pararenal aneurysms at our Institution. We treated 98 pararenal aneurysms, divided in 68 juxtarenal and 30 pararenal ones. In the juxtarenal aneurysms group, the 30 days mortality rate was 5.8% (4/68); 3 of these patients underwent urgent operation for ruptured aneurysm. In the suprarenal aneurysms group, the 30 days mortality rate was 3.3% (1/30). In conclusion pararenal aneurysm repair is a safe procedure, especially if performed electively, and represents an interesting field of research to improve surgical and anesthesiologic techniques.


Asunto(s)
Aneurisma de la Aorta Abdominal/cirugía , Anciano , Anciano de 80 o más Años , Aneurisma de la Aorta Abdominal/diagnóstico , Constricción , Femenino , Humanos , Masculino , Persona de Mediana Edad , Peritoneo , Procedimientos Quirúrgicos Vasculares/métodos
12.
Cancer Immunol Immunother ; 53(11): 955-62, 2004 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-15449042

RESUMEN

High-grade gliomas are aggressive tumors of the central nervous system characterized by endothelial cell proliferation and a high degree of vascularity. Conventional antitumoral treatments (i.e., surgery, radiotherapy, and chemotherapy) do not achieve satisfactory results (median survival in glioblastoma 12-18 months). It has been suggested that immunotherapy with xenogenic endothelial cells could slow tumor growth rate in a number of tumors in a murine model, but the study did not include gliomas. In experiments performed in our laboratory, vaccination with proliferating bovine aortic endothelium increased survival time in Fischer rats inoculated intracerebrally with 9L. Immunotherapy was also able to reduce the growth of subcutaneously injected 9L gliosarcoma cells in Fischer rats and to decrease microvessel density within the tumors, in the absence of major organ toxicity. Immunoglobulins (Ig) in the sera from vaccinated rats stained bovine aortic endothelium as well as human umbilical vein endothelium in active proliferation. Moreover, immune sera from immunized rats stained microvessels of human malignant glioma specimens and vessels of intracerebrally implanted tumors. Two proteins of MW of 11 and 19 kDa were identified by Western blot as targets of Ig elicited by vaccination. A possible future development is to select peptides/proteins suitable for vaccination in humans, avoiding the biohazards connected with xenogenic whole-cell vaccination.


Asunto(s)
Aorta/citología , Neoplasias Encefálicas/terapia , Células Endoteliales/citología , Endotelio Vascular/citología , Glioma/terapia , Inmunoterapia/métodos , Neoplasias Cutáneas/terapia , Animales , Western Blotting , Encéfalo/metabolismo , Bovinos , División Celular , Línea Celular Tumoral , Células Cultivadas , Endotelio Vascular/metabolismo , Humanos , Inmunoglobulina G/sangre , Inmunoglobulina G/química , Inmunoglobulinas/química , Inyecciones Subcutáneas , Interferón gamma/metabolismo , Microcirculación , Neoplasias/patología , Neovascularización Patológica , Ratas , Ratas Endogámicas F344 , Factores de Tiempo , Factor de Necrosis Tumoral alfa/metabolismo
13.
Eur J Histochem ; 48(4): 423-8, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15718209

RESUMEN

The binding of Lycopersicon esculentum lectin (LEA) to the vascular endothelium was studied in the central nervous system of rat, mouse and guinea pig at different developmental ages, and in a gliosarcoma model. Our observations showed that LEA consistently stained the entire vascular tree in the spinal cord and in the brain of all animal species at all developmental ages investigated. In the tumor model, the staining of the vascular network was very reproducible, enabled an easy identification of vascular profiles and displayed a higher efficiency when compared to two other commonly used vascular marker (EHS laminin and PECAM-1). Moreover, our results showed that LEA staining was comparable in both vibratome and paraffin sections and could be easily combined with other markers in double labeling experiments. These observations indicate that LEA staining may represent an effective and versatile endothelial marker for the study of the vasculature of the central nervous system in different animal species and experimental conditions.


Asunto(s)
Biomarcadores de Tumor/análisis , Neoplasias del Sistema Nervioso Central/irrigación sanguínea , Sistema Nervioso Central/irrigación sanguínea , Endotelio Vascular/química , Gliosarcoma/irrigación sanguínea , Lectinas de Plantas/metabolismo , Animales , Biomarcadores/análisis , Biomarcadores/metabolismo , Biomarcadores de Tumor/metabolismo , Endotelio Vascular/metabolismo , Femenino , Cobayas , Ratones , Embarazo , Ratas
14.
J Neurooncol ; 64(3): 193-201, 2003 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-14558594

RESUMEN

In an attempt to elucidate the mechanism(s) of action of thalidomide, a reportedly antiangiogenic molecule recently tested in the treatment of relapsing malignant gliomas, we performed an in vitro study on the following parameters: (a) effect of thalidomide on proliferation of endothelial cells; (b) effect of thalidomide on expression of alpha(v)beta3 integrin on the surface of endothelial cells; (c) effect of thalidomide on the release by endothelial cells of MMP-2, IL-8 and TNF-alpha. The results show that thalidomide inhibits endotelial cell proliferation induced by bFGF and VEGF, more so if the cells are grown on vitronectin; moreover, treatment with thalidomide reduces the release of MMP-2 and IL-8 by endothelial cells, suggesting a further pathway for the antiangiogenic activity of drug. On the other hand, thalidomide does not modify expression of alpha(v)beta3 on endothelial cells.


Asunto(s)
Inhibidores de la Angiogénesis/farmacología , Endotelio Vascular/efectos de los fármacos , Neovascularización Fisiológica/efectos de los fármacos , Talidomida/farmacología , División Celular/efectos de los fármacos , Células Cultivadas , Factores de Crecimiento Endotelial/fisiología , Endotelio Vascular/citología , Endotelio Vascular/crecimiento & desarrollo , Endotelio Vascular/metabolismo , Factor 2 de Crecimiento de Fibroblastos/fisiología , Humanos , Integrina alfaVbeta3/metabolismo , Péptidos y Proteínas de Señalización Intercelular/fisiología , Interleucina-8/metabolismo , Linfocinas/fisiología , Metaloproteinasa 2 de la Matriz/metabolismo , Neovascularización Patológica/prevención & control , Receptores de Superficie Celular/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Venas Umbilicales/citología , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial Vascular , Vitronectina/fisiología
15.
Acta Chir Belg ; 102(4): 238-47, 2002 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12244902

RESUMEN

UNLABELLED: Vascular prosthetic graft infection remains a major surgical challenge. Prevention of risk factors and antibiotic therapy can reduced but not eradicate it. Management of infected vascular grafts depends on several factors, including the location of the infected prosthesis, the extent of infection, and the underlying micro-organism. Classic treatment consists of extra-anatomic bypass grafting. The disappointing results due to the high mortality and amputation rate have kindled interest in alternative approaches, such as in situ reconstruction with antibiotic-bonded prostheses, autogenous veins or arterial allografts. PURPOSE: We focused on the treatment of aortic graft infection by means of both fresh and cryopreserved arterial allograft. Here, the experience of the Italian Collaborative Vascular Homograft Group is reported. METHODS: Between March 1994 and December 2000 seventy-nine patients with aortic graft infection were treated. The results of 68 patients are analysed. Eleven patients were treated with fresh, and 57 with cryopreserved homograft. Emergency surgical procedures were performed in 12 patients (17%). Aortoenteric fistula was diagnosed in 22 patients. The mean interval between the first procedure and the insertion of a homograft for patients with infected aortic graft was 3 years (range 1-15). The mean duration of follow-up was 30 months (range 1-68). Clinical and duplex scanning evaluation were routinely performed. Computer tomography (CT), magnetic resonance (MR), or arteriography were performed on the basis of duplex scanning results. RESULTS: The analysis was performed on 68 cases for which there were sufficient reliable data. Eleven deaths occurred during the early postoperative period (30 days), a mortality rate of 16%. There were also seventeen late deaths, a mortality rate of 25%. Eleven patients had graft occlusion; six cases were successfully treated with thrombectomy. In three cases leg amputation was necessary. The results of fresh and cryopreserved homografts were compared. No significant differences of early postoperative mortality, late mortality, homograft-related mortality, graft failure were observed. The presence of aortoenteric fistula is a negative predicting factor of perioperative early mortality, which causes a rapid decline in the survival curve. Thirty-six months after the surgery the actuarial survival of the patients was 57% and the actuarial patency of the allograft was 41%. CONCLUSION: No significant difference in terms of clinical outcome was observed when using fresh, rather than cryopreserved homografts. The only factor that significantly influenced the survival rate appeared to be the aorto-enteric fistula.


Asunto(s)
Infecciones Bacterianas/epidemiología , Infecciones Bacterianas/microbiología , Prótesis Vascular/efectos adversos , Infecciones Relacionadas con Prótesis/epidemiología , Infecciones Relacionadas con Prótesis/microbiología , Antibacterianos , Infecciones Bacterianas/tratamiento farmacológico , Implantación de Prótesis Vascular/efectos adversos , Implantación de Prótesis Vascular/métodos , Terapia Combinada , Criopreservación , Quimioterapia Combinada/administración & dosificación , Femenino , Rechazo de Injerto , Supervivencia de Injerto , Bacterias Gramnegativas/aislamiento & purificación , Bacterias Grampositivas/aislamiento & purificación , Humanos , Incidencia , Masculino , Pronóstico , Infecciones Relacionadas con Prótesis/fisiopatología , Infecciones Relacionadas con Prótesis/terapia , Reoperación , Medición de Riesgo , Trasplante Homólogo , Resultado del Tratamiento
16.
Toxicol In Vitro ; 16(4): 365-74, 2002 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12110274

RESUMEN

The rainbow trout cytochrome P4501A gene subfamily consists of two members, CYP1A1 and CYP1A3, which are induced by polycyclic aromatic hydrocarbons (PAHs). In this study, we investigated the induction of cytochrome P4501A3 in the rainbow trout (Onchorhynchus mykiss) D-11 cell line after 3-methylcholanthrene (3MC) exposure by generating chimeric constructs in which a 2.3 kb fragment or portion of the 5'-flanking region of the trout cytochrome CYP1A3 gene was fused to the firefly luciferase (Luc) gene. The constructs were then transiently transfected into the trout D-11 cells and their transcriptional activity measured by luciferase assay after treatment with different 3MC concentrations. Maximal induction following exposure to 2 microM 3MC was 2.2-fold after 72 h. Deletion of the region specifying the 5' untranslated region (5'UTR) of the mRNA encoding the CYP1A3 gene increased unstimulated luciferase activity but also led to a loss of response to 3MC treatment. This finding suggests that the region specifying the 5'UTR contains a negative element that is also involved in the transcriptional response to 3MC.


Asunto(s)
Hidrocarburo de Aril Hidroxilasas/farmacología , Oncorhynchus mykiss/fisiología , Animales , Hidrocarburo de Aril Hidroxilasas/genética , Secuencia de Bases , Carcinógenos/efectos adversos , Línea Celular , Fibroblastos/patología , Luciferasas/farmacología , Metilcolantreno/efectos adversos , Datos de Secuencia Molecular , ARN Mensajero , Transfección
17.
Br J Cancer ; 85(6): 836-44, 2001 Sep 14.
Artículo en Inglés | MEDLINE | ID: mdl-11556834

RESUMEN

Physical interaction between CDKN2A/p16 and CDK4 proteins regulates the cell cycle progression through the G1 phase and dysfunction of these proteins by gene mutation is implicated in genetic predisposition to melanoma. We analysed 15 Italian melanoma families for germ line mutations in the coding region of the CDKN2A gene and exon 2 of the CDK4 gene. One novel disease-associated mutation (P48T), 3 known pathological mutations (R24P, G101W and N71S) and 2 common polymorphisms (A148T and Nt500 G>C) were identified in the CDKN2A gene. In a family harbouring the R24P mutation, an intronic variant (IVS1, +37 G>C) of uncertain significance was detected in a non-carrier melanoma case. The overall incidence of CDKN2A mutations was 33.3%, but this percentage was higher in families with 3 or more melanoma cases (50%) than in those with only 2 affected relatives (25%). Noteworthy, functional analysis established that the novel mutated protein, while being impaired in cell growth and inhibition assays, retains some in vitro binding to CDK4/6. No variant in the p16-binding region of CDK4 was identified in our families. Our results, obtained in a heterogeneous group of families, support the view that inactivating mutations of CDKN2A contribute to melanoma susceptibility more than activating mutations of CDK4 and that other genetic factors must be responsible for melanoma clustering in a high proportion of families. In addition, they indicate the need for a combination of functional assays to determine the pathogenetic nature of new CDKN2A mutations.


Asunto(s)
Inhibidor p16 de la Quinasa Dependiente de Ciclina/genética , Quinasas Ciclina-Dependientes/genética , Mutación de Línea Germinal , Melanoma/genética , Proteínas Proto-Oncogénicas , Neoplasias Cutáneas/genética , Adulto , Anciano , Ciclo Celular , División Celular , Quinasa 4 Dependiente de la Ciclina , Inhibidor p16 de la Quinasa Dependiente de Ciclina/metabolismo , Quinasas Ciclina-Dependientes/metabolismo , Análisis Mutacional de ADN , ADN de Neoplasias/análisis , Susceptibilidad a Enfermedades , Exones , Femenino , Fase G1 , Ligamiento Genético , Pruebas Genéticas , Humanos , Italia/epidemiología , Masculino , Persona de Mediana Edad , Linaje , Reacción en Cadena de la Polimerasa , Polimorfismo Conformacional Retorcido-Simple , Transcripción Genética
18.
J Autoimmun ; 17(4): 273-80, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11771951

RESUMEN

The effects of modulation of apoptosis in experimental allergic encephalomyelitis (EAE) in Lewis rats have been investigated using a peptide of the Fas-Ligand protein (FasL-p). The peptide was administered both subcutaneously and intra-cerebro-ventricularly (i.c.v.) after EAE induction. Rats treated subcutaneously with FasL-p showed a worse clinical score as compared to saline treated animals, while i.c.v. treatment with FasL-p did not modify significantly the severity of EAE. Apoptotic lymphomonocytes (identified by TUNEL) infiltrating the brain and the spinal cord were decreased in rats treated i.c.v. with FasL-p. The data suggest that the Fas/Fas-ligand pathway may be modulated by treatments with peptides of Fas-Ligand and that it may be at work within the central nervous system in EAE.


Asunto(s)
Apoptosis/inmunología , Encefalomielitis Autoinmune Experimental/inmunología , Glicoproteínas de Membrana/inmunología , Péptidos/inmunología , Animales , Apoptosis/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Movimiento Celular/inmunología , Sistema Nervioso Central/inmunología , Sistema Nervioso Central/patología , Encefalomielitis Autoinmune Experimental/patología , Proteína Ligando Fas , Humanos , Células Jurkat , Linfocitos/inmunología , Linfocitos/patología , Glicoproteínas de Membrana/química , Péptidos/administración & dosificación , Péptidos/química , Ratas , Receptor fas/inmunología
19.
Cardiovasc Surg ; 8(7): 538-44, 2000 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11068214

RESUMEN

The operative experience and medium-term outcome achieved with longitudinally extensible ('stretch') expanded polytetrafluoroethylene (ePTFE) bifurcated grafts in patients undergoing aortoiliac or aortofemoral reconstruction for occlusive disease at our institution was reviewed. Between 1991 and 1998, 242 patients received a bifurcated stretch graft. Forty-one patients (17%) required an aortic endarterectomy, and 63 (26%) underwent femoral artery endarterectomy. 228 patients were followed for a mean of 32 months. One patient (0.4%) died perioperatively. The perioperative morbidity included cardiac (3.7%), respiratory (2.5%), and renal (3.3%) complications. Three patients required early reoperation for bleeding. Four (1.7%) grafts thrombosed within 24h of surgery; eight additional grafts (3.3%) thrombosed 5-8 months later. There were three postoperative aortic graft infections, one inguinal infection, three inguinal pseudoaneurysms, and one aortic pseudoaneurysm. Ultrasonography during follow-up showed no periprosthetic fluid collections or graft dilatations. The bifurcated ePTFE stretch graft is suitable for aortoiliac and aortofemoral reconstruction, and its physical characteristics may help to reduce graft-related complications.


Asunto(s)
Aorta/cirugía , Arteriosclerosis/cirugía , Implantación de Prótesis Vascular , Prótesis Vascular , Arteria Femoral/cirugía , Anciano , Anciano de 80 o más Años , Femenino , Arteria Femoral/diagnóstico por imagen , Humanos , Masculino , Persona de Mediana Edad , Politetrafluoroetileno/uso terapéutico , Diseño de Prótesis , Radiografía , Ultrasonografía Doppler Dúplex
20.
J Neuroimmunol ; 105(2): 109-14, 2000 Jun 26.
Artículo en Inglés | MEDLINE | ID: mdl-10742551

RESUMEN

The expression of Fas-Ligand (Fas-L) on microglia could be relevant in multiple sclerosis immunopathology. The present study was performed to evaluate in vitro the expression of Fas-L in human microglial cells both unstimulated and after stimulation with IFN-gamma, beta-IFN-1b and beta-IFN-1b+IFN-gamma. Cells were stimulated for 6,12, 24 and 48 h. Surface Fas-L was evaluated by flow cytometry, total Fas-L by Western blot, whereas mRNA for Fas-L was measured by RT-PCR. We also evaluated the capacity of microglial cells to induce, in vitro, apoptosis on Fas-positive T leukemia Jurkat cells. Our results showed a constitutive expression of Fas-L on microglia. IFN-gamma downregulated the expression of the molecule, while beta-IFN-1b and beta-IFN-1b+IFN- gamma did not. The amount of surface Fas-L was related to the ability of microglial cells to induce apoptosis in Fas-positive target cells, which was partly inhibited by blockade of the Fas-Fas-L pathway.


Asunto(s)
Glicoproteínas de Membrana/análisis , Microglía/química , Células Cultivadas , Proteína Ligando Fas , Citometría de Flujo , Humanos , Interferón beta-1a , Interferon beta-1b , Interferón beta/farmacología , Interferón gamma/farmacología , Glicoproteínas de Membrana/genética , ARN Mensajero/análisis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA